Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Chang Chun, China Clinical Trials

A listing of Chang Chun, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (203) clinical trials

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Survival for patients with high risk aggressive B-cell lymphoma is still unsatisfied. Dose-intensified immunochemotherapy might improve the outcome. But for patients who could not achieve CR after the dose-intensified induction therapy, the prognosis is poor. The DLCL002 protocol is a total therapy which including induction therapy, rescue therapy and autologous …

Phase

0.0 miles

Learn More »

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

The primary objective of this study is to evaluate and compare major pathological response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab as adjuvant treatment versus participants receiving placebo plus platinum-based doublet chemotherapy as neoadjuvant treatment followed …

Phase

0.0 miles

Learn More »

A Study of RC48 in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer.

This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with locally advanced or metastatic HER2 overexpressed biliary tract cancer who have failed first-line chemotherapy.

Phase

0.0 miles

Learn More »

AcoArt III / Arterio-venous Fistula in China

For years, first-line treatment of AVFs stenoses has been percutaneous transluminal angioplasty. However, restenosis and reintervention rates remain incredibly high and occur, according to recent studies, in up to 60% and 70% of patients at 6 and 12 months, respectively. Drug-coated balloons delivering paclitaxel at the angioplasty site have proved …

Phase N/A

0.0 miles

Learn More »

A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis

OBJECTIVES I. Confirm the inclusion of pathological stage I (pI) among clinical stage III(T3-4aNx) (cIII) diagnosis patients less than 5% II. Figure out the suitable criterion of NAC and avoid overtreatment, by examining the rate of pI rate in different diagnostic criterion groups, including cIII, TxNy(x+y>4), cN1-3, cT3-4. III. Evaluate …

Phase N/A

0.0 miles

Learn More »

Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment

Study to Evaluate Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study

Phase

0.0 miles

Learn More »

An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.

The primary objective of this observational study is: To investigate the prevalence of high PD-L1 expression in Chinese MIUBC patients. High PD-L1 expression is defined as 25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR 25% tumor associated …

Phase N/A

0.0 miles

Learn More »

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors

TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1),which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. As a novel multitarget tyrosine kinase inhibitor for tumor …

Phase

0.0 miles

Learn More »

Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer

This is a phase III, multicenter, double-blinded, placebo-controlled study of platinumCisplatin or Carboplatin plus etoposide with or without toripalimab as first Line therapy in patients with extensive stage small cell lung cancer. The purpose of this study is to evaluate the safety and efficacy of toriplimab in combination with platinumCisplatin …

Phase

0.0 miles

Learn More »

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer NSCLC

TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Phase

0.0 miles

Learn More »